GSK ZOSTER
A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered intramuscularly on a two-dose schedule to immunocompromised paediatric renal transplant recipients from 1 to 17 years of age.
- Status: coming
- Principal investigator: prof. D. Mekahli
1517-CL-1003
Phase 3, Open-Label, Uncontrolled Study for the treatment of adolescents and children with anemia associated with chronic kidney disease.
- Status: coming
- Principal investigator: prof. D. Mekahli
OPDC 307
A phase 3b multicenter open-label trial of the safety, tolerability, and efficacy of tolvaptan in infants and children 28 days to less than 18 years of age with autosomal recessive polycystic kidney disease (arpkd)
- Status: coming
- Principal investigator: prof. D. Mekahli
OPDC 204
A phase 3b multicenter open-label trial of the safety, tolerability, and efficacy of tolvaptan in infants and children 28 days to less than 12 weeks of age with autosomal recessive polycystic kidney disease (arpkd)
- Status: open
- Principal investigator: prof. D. Mekahli
OGTT ADPKP
Evaluation of the glucose metabolism in early autosomal dominant polycystic kidney disease: a multicentric study
- Status: open
- Principal investigator: prof. D. Mekahli
FIONA OLE
An 18-month, open-label, single-arm safety extension study of an age-and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria
- Status: open
- Principal investigator: prof. D. Mekahli
FIONA
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to
- Status: open
- Principal investigator: prof. D. Mekahli
COMMUTE-P
A phase iii, multicenter, single-arm study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab in pediatric patients with atypical hemolytic uremic syndrome (ahus)
- Status: open
- Principal investigator: prof. D. Mekahli
PROREAL
Multicentre, ambispetive, observational, real life study to assess the Quality of life effectiveness of ER oral cysteamine therapy (Procysbi) in Belgian patients suffering from nephropatich cystinosis
- Status: open
- Principal investigator: prof. D. Mekahli
KKI XLH Registry
An international, multicentre, prospective, non-interventional observational registry for patients with X-linked hypophosphatemia
- Status: open
- Principal investigator: prof. D. Mekahli
CINACALCET
An observational registry study to evaluate the use and safety of cinacalcet among paediatric patiënts with secondary hyperparathydroidism
- Status: open
- Principal investigator: prof. D. Mekahli
LEARNS
Prevention of relapses with Levamisole as adjuvant therapy to corticosteroids in children with first episode of idiopathic nephrotic syndrome
- Status: open
- Principal investigator: prof. D. Mekahli
PREDICT
Antibiotic propylaxis and renal damage in congenital abnormalities of the kidney and urinary tract
- Status: open
- Principal investigator: prof. D. Mekahli
ALEXION REGISTRY
An observational, non-interventional, multicenter, multi-national study of patients with atypical hemolytic- uremic syndrome
- Status: open
- Principal investigator: prof. D. Mekahli
Contact
Laatste aanpassing:
27 juni 2023